Neuropsychiatry Franchise
Sage is working to understand the underlying reasons for disorders of the brain and central nervous system (CNS). We hope this science will help us develop potential therapies that may address treatment gaps for patients with brain health disorders.
Our lead neuropsychiatry investigational compound, SAGE-718, has a unique way of modulating certain receptors in the brain. These receptors are thought to play a key role in how our brain processes information.
Sage is exploring SAGE-718 in neurodegenerative disorders like Huntington's Disease, Alzheimer's Disease, and Parkinson's Disease. Ongoing studies aim to evaluate whether SAGE-718 may have the potential to improve cognitive and/or behavioral symptoms for these difficult-to-treat disorders.
We are using our unique development approach to systemically evaluate our drug candidates in a range of neuropsychiatric disorders associated with cognitive impairment, including: